Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review

Sebastián Carranza-LiraReproductive Medicine, UMAE Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala” Instituto Mexicano del Seguro Social, MéxicoAbstract: During menopause vasomotor symptoms are one of the main complaints about which wo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Sebastián Carranza-Lira
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	estradiol drospirenone postmenopause review Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/1b46367684244238936ec75f552bdcac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b46367684244238936ec75f552bdcac
record_format	dspace
spelling	oai:doaj.org-article:1b46367684244238936ec75f552bdcac2021-12-02T00:53:43ZSafety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review1178-1998https://doaj.org/article/1b46367684244238936ec75f552bdcac2008-12-01T00:00:00Zhttps://www.dovepress.com/safety-efficacy-and-patient-acceptability-of-drospirenone-and-estradio-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Sebastián Carranza-LiraReproductive Medicine, UMAE Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala” Instituto Mexicano del Seguro Social, MéxicoAbstract: During menopause vasomotor symptoms are one of the main complaints about which women seek medical advice. For symptom control, several therapies have been used, among which hormone therapy has produced good results. One of these is estrogen monotherapy, which unfortunately may induce endometrial hyperplasia in women with an intact uterus. A progestin must be added to avoid this risk. Progestins may induce several secondary effects such as breast tenderness, hirsutism, edema and unfavorable lipid profile modifications. Recently a new progestin called drospirenone has been synthesized and used in combination with estradiol for the treatment of postmenopausal women. This progestin is derived from spironolactone, and lacks estrogenic, androgenic and glucocorticoid activities. Several studies have evaluated safety, efficacy and patient tolerability, and have shown a good profile in all these parameters. All studies agree that the combination of estradiol 1 mg plus drospirenone 2 mg is a good choice for postmenopausal women with vasomotor symptoms.Keywords: estradiol, drospirenone, postmenopause, reviewSebastián Carranza-LiraDove Medical PressarticleestradioldrospirenonepostmenopausereviewGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 59-62 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	estradiol drospirenone postmenopause review Geriatrics RC952-954.6
spellingShingle	estradiol drospirenone postmenopause review Geriatrics RC952-954.6 Sebastián Carranza-Lira Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
description	Sebastián Carranza-LiraReproductive Medicine, UMAE Hospital de Ginecología y Obstetricia “Luis Castelazo Ayala” Instituto Mexicano del Seguro Social, MéxicoAbstract: During menopause vasomotor symptoms are one of the main complaints about which women seek medical advice. For symptom control, several therapies have been used, among which hormone therapy has produced good results. One of these is estrogen monotherapy, which unfortunately may induce endometrial hyperplasia in women with an intact uterus. A progestin must be added to avoid this risk. Progestins may induce several secondary effects such as breast tenderness, hirsutism, edema and unfavorable lipid profile modifications. Recently a new progestin called drospirenone has been synthesized and used in combination with estradiol for the treatment of postmenopausal women. This progestin is derived from spironolactone, and lacks estrogenic, androgenic and glucocorticoid activities. Several studies have evaluated safety, efficacy and patient tolerability, and have shown a good profile in all these parameters. All studies agree that the combination of estradiol 1 mg plus drospirenone 2 mg is a good choice for postmenopausal women with vasomotor symptoms.Keywords: estradiol, drospirenone, postmenopause, review
format	article
author	Sebastián Carranza-Lira
author_facet	Sebastián Carranza-Lira
author_sort	Sebastián Carranza-Lira
title	Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
title_short	Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
title_full	Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
title_fullStr	Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
title_full_unstemmed	Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
title_sort	safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/1b46367684244238936ec75f552bdcac
work_keys_str_mv	AT sebastiaacutencarranzalira safetyefficacyandpatientacceptabilityofdrospirenoneandestradiolinthetreatmentofmenopausalvasomotorsymptomsareview
_version_	1718403423830802432

Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review

Ejemplares similares